Gilead Sciences Aktie
WKN: 885823 / ISIN: US3755581036
28.10.2014 21:59:35
|
Gilead Sciences Reports Q3 Non-GAAP EPS Of $1.84 - Quick Facts
(RTTNews) - Gilead Sciences, Inc. (GILD) reported third-quarter net income of $2.73 billion, or $1.67 per share compared to $788.6 million or $0.47 per share for the third quarter of 2013. Non-GAAP net income for the third quarter of 2014, which excludes acquisition-related, restructuring and stock-based compensation expenses, was $3.01 billion, or $1.84 per share. Excluding the $0.21 impact of the non-tax deductible BPD cumulative catch-up fee, Non-GAAP EPS would have been $2.05 for the third quarter of 2014.
On average, 25 analysts polled by Thomson Reuters expected the company to report profit per share of $1.92 for the quarter. Analysts' estimates typically exclude special items.
Total revenues increased to $6.04 billion compared to $2.78 billion for the third quarter of 2013. Product sales increased to $5.97 billion compared to $2.71 billion for the third quarter of 2013. Analysts expected revenue of $5.99 billion for the quarter.
Gilead updated its full year 2014 guidance. The company now expects its 2014 net product sales in the range of $22.00 billion to $23.00 billion. Diluted EPS impact of acquisition-related, restructuring and stock-based compensation expenses, is expected to be in the range of $0.63-$0.66.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Gilead Sciences Inc.mehr Nachrichten
06.05.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 beendet die Sitzung mit Verlusten (finanzen.at) | |
06.05.25 |
Schwacher Wochentag in New York: So bewegt sich der NASDAQ 100 nachmittags (finanzen.at) | |
06.05.25 |
Handel in New York: NASDAQ 100 in der Verlustzone (finanzen.at) | |
02.05.25 |
NASDAQ Composite Index-Papier Gilead Sciences-Aktie: So viel Verlust wäre bei einem Investment in Gilead Sciences von vor 10 Jahren angefallen (finanzen.at) | |
01.05.25 |
NASDAQ-Handel: NASDAQ 100 beendet den Donnerstagshandel im Plus (finanzen.at) | |
01.05.25 |
NASDAQ 100 aktuell: NASDAQ 100 mit Kursplus (finanzen.at) | |
01.05.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Mittag fester (finanzen.at) | |
01.05.25 |
Pluszeichen in New York: Zum Handelsstart Gewinne im NASDAQ 100 (finanzen.at) |
Analysen zu Gilead Sciences Inc.mehr Analysen
Aktien in diesem Artikel
Gilead Sciences Inc. | 86,93 | 0,95% |
|